Adult Neurology Clinical Trials

Study Title Description
Adult Migraine
I5Q-MC-B004 preventive Treatment of mIgraine: oUtcoMes for Patients in real-world Healthcare systems (TRIUMPH) The purpose of this study is to collect information about treatment patterns, effects, and outcomes in patients with migraine who are switching or initiating a pharmacologic treatment for migraine prevention.
Multiple Sclerosis
A Randomized, Double- blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib
The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.
The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).
The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.
COMB157G23101 An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from dimethyl fumarate or fingolimod to ofatumumab The purpose of the study is to complement the ofatumumab pivotal Phase 3
program by exploring outcomes of patients transitioning from commonly used
oral therapies, dimethyl fumarate (DMF) or fingolimod, to ofatumumab due to
breakthrough disease (defined as relapse, Gd+, or new/enlarging T2 lesions)
COMB157GUS12 A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab To assess whether participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once every 4 weeks (q4) can mount an adequate immune response to inactivated influenza vaccine as measured by humoral responses compared to participants on an iDMT.